Navigation Links
Pioneering medical nanotechnology offers new cancer breakthrough hope
Date:4/16/2009

A multi-disciplinary team of scientists from the University of Leicester could be potentially paving the way for the development of a powerful new strategy for both the early diagnosis and treatment of prostate cancer.

The research is to use cutting edge nanotechnology to identify a pioneering treatment which could also be applied to other aggressive cancers.

The University of Leicester researchers say that microscopic (5-100 nm) magnetic nanoparticles could be applied in the sensitive diagnosis and effective treatment of prostate cancer. This follows breakthrough nanotechnology research at the University.

Dr Wu Su, of the Department of Chemistry, has been awarded a grant worth 321 K. This is one of only ten Postdoctoral Research Fellowships in the Life Sciences Interface area given this year by the Engineering and Physical Sciences Research Council (EPSRC). This is the first EPSRC postdoctoral research fellowship awarded to the University of Leicester.

The highly prestigious award will allow a multi-disciplinary research team to design high-performance magnetic nanoparticles. The team consists of researchers from the University of Leicester departments of Chemistry, Physics, Cancer Studies and Molecular Medicine and Cardiovascular Sciences.

High-performance magnetic nanoparticles act as probes that show up (using Magnetic Resonance Imaging) and kill (by hyperthermia) tumour cells at a much earlier stage than conventional methods.

The pioneering technology, developed at the University of Leicester, is focused on the development of a new type of magnetic nanoparticle in which the magnetic performance is increase by a factor of ten. Targeting these magnetic nanoparticles to unique cell surface receptors present on the prostate tumour cell surface will enable efficient and specific delivery to prostate cancer cells. The approach is general and it is envisaged that these systems could be applied to other types of aggressive cancers [liver, breast, colon] in which early diagnosis and treatment is essential for recovery.

Dr Su said this technology requires a multidisciplinary approach: "Prostate cancer cure rates are predicated on early diagnosis and treatment. The technology that we are developing offers the potential of both the identification and treatment of prostate cancer in a highly selective manner."

Successful implementation of this technology would provide significant welfare benefits for patients [reducing the need for surgical removal of the prostate] and significant cost benefits for the UK health-care system.


'/>"/>

Contact: Dr Glenn Burley
gab13@le.ac.uk
01-162-522-140
University of Leicester
Source:Eurekalert  

Related medicine news :

1. Pioneering Hospital Opens In New Orleans
2. Frost & Sullivan Recognizes ValveXchanges Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages
3. Frost & Sullivan Recognizes Horphags Pioneering R&D Efforts in Health Ingredients
4. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
5. UT leads $2.5 million training program in pioneering area of genetic research
6. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
7. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
8. Dr. Paul M. Parker Is Pioneering New Advanced Lipoabdominoplasty Instead of Traditional Tummy Tuck in New Jersey
9. Pioneering Hair Transplant Doctor Explains Procedure on Oprah Winfrey Show
10. The Risk Management and Patient Safety Institute Announces Agreement With Pioneering Health Care Simulation Organization, PSO One
11. Pioneering Neurosciences Institute Sets Date for Dedication of New Facility and First-Ever International Forum on Memory and Memory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pioneering medical nanotechnology offers new cancer breakthrough hope
(Date:12/10/2016)... ... December 10, 2016 , ... ... vulnerable population in Syria’s civil war—babies and toddlers. , The situation in Syria ... are experiencing bombing, facing starvation, and dying from disease. The situation is intensifying ...
(Date:12/9/2016)... ... December 09, 2016 , ... Cellairis is a worldwide mobile device and ... iPhone , iPad and Samsung Galaxy devices with premium parts and accessories. ... to maximize convenience and accessibility for customers. While customers do their shopping, Cellairis can ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... 10th anniversary with the grand opening of the Sober College Robert Pfeifer Memorial ... two days, December 2-3, and was attended by an overwhelming amount of alumni, ...
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
Breaking Medicine Technology: